alpha-MSH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-12. Anything still debated is marked as such rather than presented as settled.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Caregiving is the ongoing physical, social, emotional support provided to people living with dementia, helping them carry out everyday activities. Since AD has no cure and it gradually renders people incapable of tending to their own needs, caregiving is essentially the treatment and must be carefully managed over the course of the disease. During the early and moderate stages, modifications to the living environment and lifestyle can increase safety and reduce caretaker burden. Examples of such modifications are the adherence to simplified routines, the placing of safety locks, the labeling of household items to cue the person with the disease or the use of modified daily life objects. Per the American Academy of Family Physicians, the use of physical restraints is discouraged. Use of the "VIPS" framework "(Valuing people, Individualised care, Personal perspectives, Social environment)" has been shown to reduce hours per day of restraint. If eating becomes problematic, food will need to be prepared in smaller pieces or even puréed. When swallowing difficulties arise, the use of feeding tubes may be required. In such cases, the medical efficacy and ethics of continuing feeding is an important consideration of the caregivers and family members. During the final stages of the disease, treatment is centred on relieving discomfort until death, often with the help of hospice. The wellbeing of caregivers themselves is an important aspect of AD caregiving.
== Diagnosis == Screening involves an MRI scan to identify and diagnose tumors in the subarachnoid region of the brain. MRI can make a diagnosis even without an analysis of the cerebrospinal fluid but it can sometimes be difficult to detect because MRI scans cannot always pick up the problem. Diagnosis is most commonly made by lumbar puncture to detect malignant cells in the CSF, although the tests may be negative in roughly 10% of patients. Diagnosis often requires a high index of suspicion and is confirmed by neuroimaging and cerebrospinal fluid analysis. CSF examination is the most useful diagnostic tool for NM. Patients with suspected NM should undergo one or two lumbar punctures, cranial magnetic resonance imaging (MRI), spinal MRI, and a radioisotope CSF flow study to rule out sites of CSF block. If the cytology remains negative and radiological studies are not definitive, consideration may be given to ventricular or lateral cervical spine CSF analysis based on the suspected site of predominant disease. Consideration of signs, symptoms, and neuroimaging can help with the placement to where CSF is drawn. Median time of diagnosis from initial primary cancer diagnosis is between 76 days and 17 months.
and Israeli efforts to supply the Contras with arms, the U.S. ignored Noriega's use of weapons-shipment networks to smuggle drugs into the U.S. Noriega was reported to have played a role in the Iran–Contra affair in the mid-1980s. There are varying reports about how much Noriega was paid by United States sources. In early 1990, Noriega biographer Frederick Kempe reported that the United States gave Noriega or his intelligence services annual payments in the range of $110,000 in 1976 increasing to $185,000 to $200,000 when he came to power during the Reagan administration. Dinges said that he could find no one willing to confirm persistent reports that he received a $200,000 per year stipend from the CIA. Prior to and during Noriega's trial, Noriega's lead attorney Frank A. Rubino claimed that Noriega had received $11 million in payments from the CIA. In January 1991, federal prosecutors filed a financial report indicating that Noriega had received a total of $322,000 from the United States Army and the CIA over a 31-year period from 1955 to 1986. They stated that the release of information was to rebut allegations from defense attorneys that Noriega had been paid "millions of dollars" from the CIA. These payments included a total of $76,039 as "gifts and incentives" from the CIA. Despite Noriega's alliance with the U.S., he also maintained close relationships with bitter enemies of the U.S., including Cuba, Libya, and Nicaragua.
Sources: en.wikipedia.org
Meristematic cells give rise to various organs of the plant and keep the plant growing. There are two types of meristematic tissues 1) Apical Meristem 2) Lateral Meristem. The Apical Meristem is of two types; the shoot apical meristem (SAM) gives rise to organs like the leaves and flowers, while the root apical meristem (RAM) provides the meristematic cells for the future root growth. SAM and RAM cells divide rapidly and are considered indeterminate, in that they do not possess any defined end status. In that sense, meristematic cells are frequently compared to animal stem cells, which have an analogous behavior and function. Within plants, SAM cells play a major role in the overall growth and development, this is due to the fact that all cells making up the major parts of the plant come from the shoot apical meristem (SAM). There are three different important areas found within the SAM and they include the central zone, the peripheral zone, and the rib meristem. Each of these areas play an important role in the production of new stem cells within the SAM. All SAMs are usually dome shaped and have structures that are layered and are described as the tunica and corpus. CLV3 plays an important role in regulating the production of stem cells within the Central Zone region of the (SAM), this is also true for the cell promoting WUSCHEL (WUS) gene. The combination of these two genes regulates stem cell production by WUS negatively or positively regulating the production of stem cells by controlling the CLV3 gene.
Some organizations hold proceedings before tribunals relating to their organization to be confidential, and in some instances have threatened disciplinary action should an employee disclose any of the relevant information. Such confidentiality has been criticized as a lack of transparency. The immunities also extend to employment law. In this regard, immunity from national jurisdiction necessitates that reasonable alternative means are available to effectively protect employees' rights; in this context, a first instance Dutch court considered an estimated duration of proceedings before the Administrative Tribunal of the International Labour Organization of 15 years to be too long. An international organization does not pay taxes, is difficult to prosecute in court and is not obliged to provide information to any parliament.
=== Nonsocial cognition theories === Nonsocial cognition theories focuses on nonsocial or general processing: the executive functions such as working memory, planning, and inhibition. In his review, Kenworthy states that "the claim of executive dysfunction as a causal factor in autism is controversial", however, "it is clear that executive dysfunction plays a role in the social and cognitive deficits observed in individuals with autism". Tests of core executive processes such as eye movement tasks indicate improvement from late childhood to adolescence, but performance never reaches typical adult levels. A strength of this theory is predicting stereotyped behavior and narrow interests; two weaknesses are that executive function is hard to measure and that executive function deficits have not been found in young children with autism.
On 3 May, the South China Morning Post reported that two US Air Force C-17 planes were spotted landing at Beijing Capital International Airport. These planes are routinely used to transport the president or vice-president's motorcade and support gear—including the "heavily armed presidential motorcade" known as "The Beast"—before overseas trips. The incident therefore ignited speculation that it was in preparation for Trump's planned visit to China. On 6 May, two black SUVs with tinted windows and US government plates were spotted in a Beijing highway, thought to be in preparation of Trump's visit. On 11 May, Chinese foreign ministry confirmed that Trump will pay a state visit to China from 12 to 15 May. The US principal deputy press secretary Anna Kelly stated that Trump will visit the Temple of Heaven and a state banquet during this visit. On 11 May, Trump announced he would have a discussion with Xi Jinping on the matter of arms sales to Taiwan, breaking with the Six Assurances. Trump posted on Truth Social and stated that he was looking forward to trip to China, which he called "an amazing country". On 13 May, the Chinese Embassy to the US posted on X stating "four red lines in China–US relations must not be challenged", namely "the Taiwan Question", "Democracy and Human Rights", "Paths and Political Systems" and "China's Development Right".
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.